TY - CHAP M1 - Book, Section TI - Cutaneous Lymphomas A1 - Huen, Auris A2 - Kantarjian, Hagop M. A2 - Wolff, Robert A. A2 - Rieber, Alyssa G. Y1 - 2022 N1 - T2 - The MD Anderson Manual of Medical Oncology, 4e AB - KEY CONCEPTSCutaneous lymphomas are a heterogenous group of B- and T-lymphocyte infiltration to the skin with varying clinical behaviors and prognoses.Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL) with typical indolent course, but a subset of patients can progress to more advanced stages involving nodal and blood compartments.Sézary syndrome (SS) is a leukemic variant of CTCL with a more aggressive course. In many patients, skin biopsy is nondiagnostic because it does not reveal malignant cells, and diagnosis is made by peripheral blood flow cytometry or Sézary cell count.The treatment of patients with CTCL is guided by stage and distribution of the skin involvement. The initial treatment approach to skin-limited disease is embodied by the use of skin-directed treatment modalities.Two newly approved treatment options for patients with relapsed refractory MF and SS include brentuximab vedotin and mogamulizumab, which target skin and blood compartments of disease, respectively.Primary cutaneous B-cell lymphomas should be distinguished from secondary metastasis of B-cell lymphoma to the skin and are typically associated with an indolent disease course and a favorable prognosis. SN - PB - McGraw Hill Education CY - New York, NY Y2 - 2024/03/29 UR - hemonc.mhmedical.com/content.aspx?aid=1190833319 ER -